COMPARATIVE ANALYSIS OF HEPATOPROTECTORS IN WISTAR RATS WITH EXPERIMENTALLY INDUCED METABOLICALLY ASSOCIATED FATTY...

Area of Science:

• Endocrinology
• Hepatology
• Metabolic Diseases

Background:

• Obesity pandemic drives metabolic syndrome, increasing metabolic-associated fatty liver disease (MAFLD) and type 2 diabetes mellitus (T2DM) prevalence.
• MAFLD and T2DM share similar pathobiology, leading to frequent co-occurrence in patients.
• This dual diagnosis can potentiate disease progression and increase complication risks, often overlooked by specialists.

Purpose of the Study:

• To review current evidence on MAFLD and T2DM from a diabetologist's viewpoint.
• To highlight the overlooked coexistence and risks associated with MAFLD and T2DM.
• To propose optimal, integrated management strategies for patients with both conditions.

Main Methods:

• Comprehensive literature review focusing on diabetology perspectives.
• Analysis of current evidence regarding MAFLD and T2DM pathobiology and clinical presentation.
• Synthesis of management strategies for coexisting MAFLD and T2DM.

Main Results:

• MAFLD and T2DM frequently coexist, exacerbating individual disease outcomes.
• Current management often fails to address the interconnected nature of these conditions.
• A multidisciplinary team approach is essential for effective patient care.

Conclusions:

• Integrated management of MAFLD and T2DM is critical for improving patient outcomes.
• Enhanced collaboration between hepatologists and diabetologists is necessary.
• Holistic care involving dieticians and surgeons can optimize treatment for complex cases.